Efficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma.
J Drugs Dermatol
; 23(7): 529-537, 2024 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-38954613
ABSTRACT
BACKGROUND:
Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.OBJECTIVE:
To evaluate the safety, efficacy, and patient satisfaction of a novel nano-formulated cysteamine and TXA combination cream in treating subjects with epidermal melasma.METHODS:
Fifty (50) randomized subjects participated and received cysteamine and TXA combination cream. The cream was applied for 30 minutes daily for a 3-month duration. Treatment effectiveness, safety, patient satisfaction, and adherence were evaluated.RESULTS:
A continuous improvement in melasma was observed, with modified Melasma Area and Severity Index (mMASI) scores improving by 40%, 57%, and 63% at 30, 60, and 90 days, respectively. The primary endpoint of a decrease in mMASI scores was met, with 91% of participants experiencing melasma improvement. Patient Satisfaction and Patient Adherence scores indicated satisfaction. Convenience exhibited the strongest correlation with patient adherence.Conclusion:
Nano-formulated cysteamine and TXA combination cream showed significant efficacy in decreasing mMASI score while demonstrating a strong safety profile and patient satisfaction. J Drugs Dermatol. 2024;23(7)529-537. doi10.36849/JDD.7765R1.
Full text:
1
Database:
MEDLINE
Main subject:
Tranexamic Acid
/
Patient Satisfaction
/
Cysteamine
/
Medication Adherence
/
Melanosis
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2024
Type:
Article